Abstract | BACKGROUND: STUDY DESIGN: Four hundred fifty-three women were randomized to receive a 24/4 regimen of drospirenone 3 mg/ ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg; n=230) or a 21/7 regimen of desogestrel 150 mcg/EE 20 mcg (DSG 150 mcg/EE 20 mcg; n=223), and recorded bleeding daily over 7 treatment cycles. RESULTS: The duration [mean 4.7 (SD 1.5)-5.2 (SD 2.2) days in the drsp 3 mg/EE 20 mcg 24/4 group and 5.1 (SD 1.5)-5.4 (SD 2.1) days in the DSG 150 mcg/ EE 20 mcg group] and maximum intensity ("normal bleeding" for >50% of all subjects) of scheduled bleeding in Cycles 1-6 was comparable between treatment groups. The incidence of unscheduled bleeding during Cycles 2-6 was also similar between the two groups (drsp 3 mg/EE 20 mcg, 8.8-17.3%; DSG 150 mcg/ EE 20 mcg, 9.4-16.3%). CONCLUSION: Drsp 3 mg/EE 20 mcg 24/4 achieved an acceptable bleeding profile with reliable cycle control, comparable with an established formulation.
|
Authors | Leena Anttila, Michael Kunz, Joachim Marr |
Journal | Contraception
(Contraception)
Vol. 80
Issue 5
Pg. 445-51
(Nov 2009)
ISSN: 1879-0518 [Electronic] United States |
PMID | 19835718
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstenes
- Contraceptives, Oral, Combined
- drospirenone and ethinyl estradiol combination
- ethinyl estradiol-desogestrel combination
- Ethinyl Estradiol
- Desogestrel
|
Topics |
- Adolescent
- Adult
- Androstenes
(adverse effects, pharmacology)
- Contraceptives, Oral, Combined
(adverse effects, pharmacology)
- Desogestrel
(adverse effects, pharmacology)
- Ethinyl Estradiol
(adverse effects, pharmacology)
- Female
- Humans
- Menstrual Cycle
(drug effects)
- Menstruation Disturbances
(chemically induced)
- Metrorrhagia
(chemically induced)
- Patient Satisfaction
(statistics & numerical data)
- Treatment Outcome
- Young Adult
|